Formation Bio Raised $600 Million for a Debut Fund to Acquire and Develop Clinical-Stage Drug Programs
Thursday, October 29, 2026 · first reported by HedgeCo
Formation Bio has announced its debut Drug Development Accelerator Fund with $600 million in capital commitments. The vehicle will finance 10 to 15 clinical-stage drug programs over three to five years, acquiring or in-licensing Phase 1 and Phase 2 assets. Limited partners include research foundations, endowments, hospitals and philanthropic organizations.
- Firm
- Formation Bio
- Fund
- Formation Bio Drug Development Accelerator Fund
- Size
- $600M
- Stage
- Target
- Asset class
- Private equity, Venture
- Geography
- North America
The summary and fields above are extracted from the published reports and can contain errors. The linked articles are the source of record.
Coverage
1 source- CD&R raises $20bn towards $26bn flagship buyout fund targetPrivate Equity Wire
- OpenAI-backed Thrive Holdings acquires ADTTechCrunch +2
- Endeavour seeks $950m for latest Western US-focused fundPEI Private Equity
- GTCR closes in on $15bn hard-cap for Fund XVPEI Private Equity
- Advent raises $30 billion for latest buyout, mid-market fundsReuters +18
- Acuity agreed to acquire Parameter Technologies, a data center leak detection and battery monitoring makerPrivate Equity Professional
Got news? Send it to us →